Spero Therapeutics (NASDAQ: SPRO) and Ascendis Pharma A/S (NASDAQ:ASND) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Profitability

This table compares Spero Therapeutics and Ascendis Pharma A/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spero Therapeutics N/A N/A N/A
Ascendis Pharma A/S -4,687.42% -64.10% -58.19%

Institutional & Insider Ownership

78.9% of Ascendis Pharma A/S shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Spero Therapeutics and Ascendis Pharma A/S’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spero Therapeutics N/A N/A N/A N/A N/A
Ascendis Pharma A/S $5.10 million 260.08 -$75.80 million ($3.64) -10.02

Spero Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S.

Analyst Recommendations

This is a summary of current ratings for Spero Therapeutics and Ascendis Pharma A/S, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spero Therapeutics 0 1 3 0 2.75
Ascendis Pharma A/S 0 1 5 0 2.83

Spero Therapeutics currently has a consensus target price of $28.00, suggesting a potential upside of 144.76%. Ascendis Pharma A/S has a consensus target price of $36.45, suggesting a potential downside of 0.05%. Given Spero Therapeutics’ higher probable upside, equities analysts plainly believe Spero Therapeutics is more favorable than Ascendis Pharma A/S.

Spero Therapeutics Company Profile

SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market. Its courses are available in text and video-interactive formats, live education and webinars. The Company also designs, produces and delivers customized programs and technology, as well as offer a range of customer service, course hosting, accreditation tracking and administration, and e-marketing opportunities to its clients. The Company’s customers include professional service firms and companies of all sizes; individuals who purchase its courses, programs or subscriptions on a retail basis, and numerous professional organizations and their respective members.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

Receive News & Ratings for Spero Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.